Abstract:
According to the literature, the use of determination of microRNA (miRNA) expression as a molecular diagnostic
marker in this category of patients may be highly effective in solving these complications. Despite many studies, there
is still no clear opinion regarding the use of treatment methods for patients with RA and liver diseases. If we can clarify
the etiology and pathogenesis of liver damage in RA depending on the expression of microRNAs or stratify risk groups
for liver damage in RA according to these biomarkers, it will be possible to achieve some progress in the treatment of
these comorbid pathologies